Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study

BACKGROUND: Limited second-line therapeutic options are available for metastasis pancreatic cancer (mPC). We aimed to explore the efficacy and safety of oxaliplatin plus irinotecan (IROX) in mPC patients. METHODS: This is an open-label, Phase 2, randomized study of mPC patients (aged 18–75 years) wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hangyu, Tong, Zhou, Liu, Lulu, Fu, Qihan, Zhu, Xudong, Dai, Xiaomeng, Bao, Xuanwen, Fang, Weijia, Zheng, Yi, Zhao, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897170/
https://www.ncbi.nlm.nih.gov/pubmed/36751477
http://dx.doi.org/10.1093/gastro/goac088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897170/
https://www.ncbi.nlm.nih.gov/pubmed/36751477
http://dx.doi.org/10.1093/gastro/goac088

Ejemplares similares